Cover Image

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standar...

Full description

Saved in:
Bibliographic Details
Main Authors: Schubert, Maria-Luisa (Author) , Bethge, Wolfgang A. (Author) , Ayuk, Francis A. (Author) , von Bonin, Malte (Author) , Vucinic, Vladan (Author) , Wagner-Drouet, Eva Marie (Author) , Subklewe, Marion (Author) , Baldus, Claudia D. (Author) , Glass, Bertram (Author) , Marks, Reinhard (Author) , Mougiakakos, Dimitrios (Author) , Schroers, Roland (Author) , Stelljes, Matthias (Author) , Topp, Max S. (Author) , Wulf, Gerald (Author) , Kröger, Nicolaus (Author) , Dreger, Peter (Author)
Format: Article (Journal) Editorial
Language:English
Published: October 13, 2023
In: Blood advances
Year: 2023, Volume: 7, Issue: 20, Pages: 6191-6195
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011203
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2023011203
Get full text
Author Notes:Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger, on behalf of the German Lymphoma Alliance and the German Registry for Stem Cell Transplantation
Description
Summary:TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standard of care for the treatment of patients with relapsed and/or refractory (r/r) LBCL, including PMBCL beyond second treatment line.3,4 Axicabtagene ciloleucel (axi-cel) has been the first CART therapy specifically approved for treatment of PMBCL in this setting. However, because of the rarity of the disease, information on safety and efficacy of CARTs in PMBCL is limited.5-7 Here, we compared course and outcome of axi-cel-treatment in patients with r/r PMBCL and those with r/r diffuse LBCL (DLBCL), not otherwise specified.
Item Description:Gesehen am 31.01.2024
Physical Description:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011203

Similar Items